The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of GS-9450 in Subjects With Nonalcoholic Steatohepatitis
Open accessAbstract
In nonalcoholic steatohepatitis (NASH), the extent of hepatocyte apoptosis correlates with disease severity. Reducing hepatocyte apoptosis with the selective caspase inhibitor GS-9450 has a potential for altering the course of the liver disease. In this phase 2, double-blind study, 124 subjects with biopsy-proven NASH were randomized to once-daily placebo or 1, 5, 10, or 40 mg GS-9450 for 4 weeks. Absolute and percent changes from baseline in ALT levels, AST levels, and caspase-3–cleaved cytokeratin (CK)-18 fragments at week 4 were assessed by an analysis of covariance model with adjustment for baseline values. In the 40-mg group, mean (SD) ALT decreased by 47 (43) U/L from baseline to week 4 ( P < 0.0001 versus placebo), and the proportion of subjects with normal ALT increased from 0% to 35% at week 4. In the 40-mg group, mean AST decreased by 13 U/L from baseline (not significant), and the proportion with normal AST increased from 20% at baseline to 48% at week 4. By week 4, mean CK-18 fragment levels had decreased to 393 (723) U/L in the GS-9450 10-mg group and 125 (212) U/L in the 40-mg group, but these reductions were not statistically significant. No serious adverse events were reported during treatment, and the percentage of subjects with at least one treatment-emergent grade 3 or 4 laboratory abnormality ranged from 11.5% to 17% across the GS-9450 treatment groups versus 35% in the placebo group. Conclusion : GS-9450 treatment induced significant reductions in ALT levels in NASH patients. Reductions in CK-18 fragment levels also occurred, although they were not statistically significant. At appropriate therapeutic indices, selective caspase inhibitors may be a promising treatment option in patients with NASH. (Hepatology 2012)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citationHepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis
Feldstein, A. E., Canbay, A., Angulo, P., Taniai, M., Burgart, L. J., Lindor, K. D., & Gores, G. J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00907-7 · Cited by 1,085
The many roles of FAS receptor signaling in the immune system
Strasser, A., Jost, P. J., & Nagata, S. (2009) · Immunity · doi:10.1016/j.immuni.2009.01.001 · Cited by 968
Aithal, G. P., Thomas, J. A., Kaye, P. V., Lawson, A., Ryder, S. D., Spendlove, I., Austin, A. S., Freeman, J. G., Morgan, L., & Webber, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.047 · Cited by 721 · cited 2×
“Headache 4 (15) 7 (27) 4 (17) 4 (16) 5 (22)”
Ratziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann–Heurtier, A., Serfaty, L., Podevin, P., Lacorte, J., Bernhardt, C., Bruckert, E., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.078 · Cited by 625
Self-citationApoptotic Body Engulfment by a Human Stellate Cell Line Is Profibrogenic
Canbay, A., Taimr, P., Torok, N., Higuchi, H., Friedman, S., & Gores, G. J. (2003) · Laboratory Investigation · doi:10.1097/01.lab.0000069036.63405.5c · Cited by 417
Cited by
Lipotoxicity and the gut-liver axis in NASH pathogenesis
Marra, F., & Svegliati-Baroni, G. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.014 · Cited by 847
Nonalcoholic fatty liver disease
Brunt, E. M., Wong, V. W.-S., Nobili, V., Day, C. P., Sookoian, S., Maher, J. J., Bugianesi, E., Sirlin, C. B., Neuschwander-Tetri, B. A., & Rinella, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.80 · Cited by 818
Cell Death and Cell Death Responses in Liver Disease: Mechanisms and Clinical Relevance
Luedde, T., Kaplowitz, N., & Schwabe, R. F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.07.018 · Cited by 759
Musso, G., Cassader, M., Rosina, F., & Gambino, R. (2012) · Diabetologia · doi:10.1007/s00125-011-2446-4 · Cited by 661
Noninvasive biomarkers in NAFLD and NASH — current progress and future promise
Wong, V. W.-S., Adams, L. A., de Lédinghen, V., Wong, G. L.-H., & Sookoian, S. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0014-9 · Cited by 614
Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum
Hardy, T., Oakley, F., Anstee, Q. M., & Day, C. P. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044224 · Cited by 611
Apoptosis and necroptosis in the liver: a matter of life and death
Schwabe, R. F., & Luedde, T. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0065-y · Cited by 582
Recent insights into the pathogenesis of nonalcoholic fatty liver disease
Arab, J. P., Arrese, M., & Trauner, M. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043617 · Cited by 573
Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease
Mota, M., Banini, B. A., Cazanave, S. C., & Sanyal, A. J. (2016) · Metabolism · doi:10.1016/j.metabol.2016.02.014 · Cited by 570
Self-citationNon-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies
Musso, G., Cassader, M., & Gambino, R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.3 · Cited by 412
Molecular Mechanisms That Link Oxidative Stress, Inflammation, and Fibrosis in the Liver
Ramos-Tovar, E., & Muriel, P. (2020) · Antioxidants · doi:10.3390/antiox9121279 · Cited by 340
Molecular mechanisms of hepatic apoptosis
Wang, K. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.499 · Cited by 329
Cell death pathways: intricate connections and disease implications
Kist, M., & Vucic, D. (2021) · The EMBO Journal · doi:10.15252/embj.2020106700 · Cited by 321
A positive feedback loop between RIP3 and JNK controls non‐alcoholic steatohepatitis
Gautheron, J., Vucur, M., Reisinger, F., Cardenas, D. V., Roderburg, C., Koppe, C., Kreggenwinkel, K., Schneider, A. T., Bartneck, M., Neumann, U. P., et al. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201403856 · Cited by 314
Barreyro, F. J., Holod, S., Finocchietto, P. V., Camino, A. M., Aquino, J. B., Avagnina, A., Carreras, M. C., Poderoso, J. J., & Gores, G. J. (2015) · Liver International · doi:10.1111/liv.12570 · Cited by 294
Cell Death in Liver Diseases: A Review
Shojaie, L., Iorga, A., & Dara, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249682 · Cited by 293
Mouse models of nonalcoholic steatohepatitis in preclinical drug development
Hansen, H. H., Feigh, M., Veidal, S. S., Rigbolt, K. T., Vrang, N., & Fosgerau, K. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.06.007 · Cited by 270
Features, Diagnosis, and Treatment of Nonalcoholic Fatty Liver Disease
Torres, D. M., Williams, C. D., & Harrison, S. A. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.03.011 · Cited by 268
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Kang, S. H., Lee, H. W., Yoo, J.-J., Cho, Y., Kim, S. U., Lee, T. H., Jang, B. K., Kim, S. G., Ahn, S. B., Kim, H., et al. (2021) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2021.0178 · Cited by 267
Current efforts and trends in the treatment of NASH
Ratziu, V., Goodman, Z., & Sanyal, A. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.041 · Cited by 262
Self-citationNon-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches
Schuppan, D., & Schattenberg, J. M. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12212 · Cited by 256
Athyros, V. G., Alexandrides, T. K., Bilianou, H., Cholongitas, E., Doumas, M., Ganotakis, E. S., Goudevenos, J., Elisaf, M. S., Germanidis, G., Giouleme, O., et al. (2017) · Metabolism · doi:10.1016/j.metabol.2017.02.014 · Cited by 219
Protective Roles for Caspase-8 and cFLIP in Adult Homeostasis
Weinlich, R., Oberst, A., Dillon, C. P., Janke, L. J., Milasta, S., Lukens, J. R., Rodriguez, D. A., Gurung, P., Savage, C., Kanneganti, T. D., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.045 · Cited by 157
“The therapeutic use of pan-caspase inhibitors has been proposed and, to date, no severe toxic effects of these inhibitors have been reported in mice (Callus and Vaux, 2007) or humans (Pockros et al., 2007; Ratziu et al., 2012).”
BackgroundNonalcoholic fatty liver disease – current status and future directions
Demir, M., Lang, S., & Steffen, H. (2015) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12291 · Cited by 105
Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver disease
Fealy, C. E., Haus, J. M., Solomon, T. P. J., Pagadala, M., Flask, C. A., McCullough, A. J., & Kirwan, J. P. (2012) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00127.2012 · Cited by 102
Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis
Zhou, J., Huang, N., Guo, Y., Cui, S., Ge, C., He, Q., Pan, X., Wang, G., Wang, H., & Hao, H. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.11.004 · Cited by 99
A critical review of endpoints for non-cirrhotic NASH therapeutic trials
Ratziu, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.12.001 · Cited by 74
Self-citation
Metadata
- Authors
- Ratziu, V., Sheikh, M. Y., Sanyal, A. J., Lim, J. K., Conjeevaram, H., Chalasani, N., Abdelmalek, M., Bakken, A., Renou, C., Palmer, M., Levine, R. A., Bhandari, R. B., Cornpropst, M., Liang, W., King, B., Mondou, E., Rousseau, F. S., McHutchison, J., & Chojkier, M.
- Venue
- Hepatology
- Published
- 2012-02
- Volume
- 55
- Issue
- 2
- Pages
- 419-428
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2071841244
- Cited by
- 164
- References
- 6
- FWCI
- 9.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.